Work Overview
LATEST PROJECTS
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque
BIOMDRIN develops cutting-edge nutraceuticals for disease prevention
The drug discovery process transferred to nutraceuticals
The drug discovery process transferred to nutraceuticals
THE TEAM
Josué Jiménez Vázquez, Ph.D
Co-Founder and Chief Science Officer
Josué developed the technology and bases that seeded Biomdrin after completing his Ph.D. in biomaterials.
Josué is a passionate and visionary scientific leader. With experience in precision medicine, tissue engineering, data science, and machine learning, he leads our scientific strategy and guides our research and development team to the cutting edge of innovation.
Using Biomdrin's technology, he formulated and described the scientific principles of VeCollal.
Josue speaks Spanish and English. He enjoys traveling and walking in nature to think and talk about new ideas.
Tony Van Campen
Co-founder and CCO
Tony and Josué worked together on succesfully developing and bringing VeCollal to market.
With 25 years of commercial experience and a rich entrepreneurial background, Tony is strong in business development, visionary strategy and partnerships.
A former pro athlete, married with 1 son, Tony speaks 5 languages and lives in Antwerp, Belgium.
​
Patrick van der Linden
Co-Founder and CFO/COO
Patrick van der Linden is a senior executive with more than 25 years experience, of which 15 years at board level.
Patrick delivers business transformation and optimisation in start-up, growth and restructuring situations. He is strong in strategy and operational execution.
He has a broad international experience having worked and lived in The Netherlands, Germany, Belgium, Russia, China and the United Kingdom.
Patrick holds a business degree and an MBA and he speaks Dutch, English, German and French. He is married with 2 children and lives in Belgium.
OUR VISION
.png){kind=small}
Our vision at BIOMDRIN is to empower people to take control of their health by developing cutting-edge nutraceuticals that prevent disease.
We believe that everyone deserves access to safe and effective preventive solutions, and we are committed to harnessing the power of nature through AI to develop innovative products that promote wellness and longevity.
We envision a future where disease prevention is the norm, not the exception.
Fast go-to-market with efficient, scientifically validated nutraceuticals
Our big data and machine learning-powered platform allow us to identify new therapeutic targets and formulate products swiftly, enabling us to bring them to market within an average of 6 months.
Proof of concept
VeCollal® the first science-based vegan alternative to type I animal collagen supplements, is already commercially exploited.
​
The target of VeCollal® was to replicate the human type I collagen amino acid profile with vegan amino acids and specifically induce collagen synthesis using plant-derived biomolecules.
​
The results obtained were an increase of collagen production by almost 135% in fibroblast treated with VeCollal®. In clinical trials, the average value of skin collagen density was significantly increased by 13.9%, and wrinkles were decreased by 14.1% after consuming VeCollal® sachet for 4 weeks. VeCollal® consumption also has shown positive effects on skin texture, hydration, and redness.
Pipeline
Target Areas and Next-Generation Nutraceutical Solutions
At Biomdrin, we leverage a powerful AI-driven approach to unlock the driving mechanisms behind diseases and biological processes. This empowers us to pioneer targeted nutraceutical solutions designed to address a wide range of health concerns.
Aging
We delve into the genetic underpinnings of aging to identify novel targets and develop next-generation nutraceutical solutions to enhance lifespan and well-being.
Energy
Recognizing the vital link between energy metabolism and aging, Biomdrin is developing innovative nutraceutical formulations to boost energy levels, combat fatigue, and enhance exercise performance.
Muscle
Age-related decline in muscle strength and performance is a significant concern. Our targeted nutraceutical formulations are designed to improve muscle function and reduce muscle fiber loss.
Biomimetic mysin formulations enable to improve peak athletic performance.
Obesity
The global rise in obesity is a major health threat. Biomdrin is exploring the molecular mechanisms of obesity and its connection to aging to identify promising therapeutic targets for the development of effective weight-management solutions.
Diabetes
By unraveling the molecular changes associated with the progression of type 2 diabetes, Biomdrin is pioneering nutraceutical formulations to help prevent or delay the onset of this debilitating condition.
Gut health
Gut health encompasses a range of positive factors, including optimal nutrient absorption, a balanced gut microbiome, and a robust immune system. Biomdrin utilizes data-driven formulations to design novel nutraceuticals that promote optimal gut health.
Menopause
Menopause is a critical stage in a woman's life that can significantly impact quality of life. Biomdrin is committed to developing nutraceutical solutions to delay the onset of menopause and alleviate associated symptoms.
Mental Disorders
The global prevalence of mental disorders is on the rise. Biomdrin is at the forefront of research into nutraceutical formulations designed to target the underlying factors that contribute to the development and progression of mental health conditions.
The team at Biomdrin is actively looking for investors who are interested in supporting the further growth of the company
